Trials / Completed
CompletedNCT04166474
Drug Interactions Between Dolutegravir and Escalating Doses of Rifampicin
- Status
- Completed
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 36 (actual)
- Sponsor
- Helen Reynolds · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This is a drug interaction study in HIV negative, TB-monoinfected participants coming to the end of continuation phase of TB therapy, to study the pharmacokinetic changes to dolutegravir when administered with standard, medium and high dose rifampicin.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Dolutegravir | Dosed at 50 mg bd on 3 separate occasions with low, medium and high doses of rifampicin. Dosed at 50 mg od without rifampicin. |
Timeline
- Start date
- 2021-11-18
- Primary completion
- 2024-02-07
- Completion
- 2024-02-07
- First posted
- 2019-11-18
- Last updated
- 2024-08-13
Locations
2 sites across 2 countries: South Africa, Uganda
Source: ClinicalTrials.gov record NCT04166474. Inclusion in this directory is not an endorsement.